| National Dentex Announces End of "Go-Shop" Period (Business Wire) NATICK, Mass.----National Dentex Corporation , one of the largest owner/operators of dental laboratories in North America, today announced the expiration, at 11:59 p.m. on May 12, 2010, of the “go-shop” period during which it was permitted to solicit alternative proposals to its proposed merger with an affiliate of GeoDigm Corporation , a technology based manufacturing and laboratory company and a portfolio company of Welsh, Carson, Anderson & Stowe XI, L.P. . us.rd.yahoo.com |
Maine Seeks Health-Care Waiver Maine's insurance regulator asked the Obama administration to temporarily exempt the state's health plans from a key provision of the federal health overhaul that would affect their profits. online.wsj.com |
Merck Charts China Expansion With Sinopharm Deal The Burrill Report submits: By Michael FitzhughMerck (MRK) and China's largest pharmaceutical and health company, Sinopharm, are collaborating to increase access to and sales of human papillomavirus and other selected vaccines in that country, one of the world’s fastest growing pharmaceutical markets. The partners signed a statement of mutual intent to cement the deal and say they’ll also discuss the potential for promoting and marketing Merck’s pharmaceutical products in China. Complete Story » seekingalpha.com |
Positive Data on Vivus’ Weight-Loss Drug Qnexa Zacks.com submits: Vivus Inc. (VVUS) recently announced positive data from a two-year trial of its weight loss, once-daily pill Qnexa. The data, reported from the extended 52-week SEQUEL study, covered 675 overweight or obese patients. The SEQUEL trial followed the 56-week CONQUER trial.The patients who took the highest dose of Qnexa during the total 108 weeks of the study experienced and maintained an average weight loss of 11.4% or 26 pounds. The candidate was well tolerated in the SEQUEL study, with the most common adverse events being constipation, tingling, dry mouth, altered taste and insomnia.Complete Story » seekingalpha.com |
EpiCept's Promising Leukemia Drug: A Buying Opportunity? Over the past six weeks or so, my interest in EpiCept (EPCT) has heightened since the company was dealt a unexpected regulatory setback with their new drug application (NDA) for Ceplene, a novel cancer drug indicated to treat patients with Acute Myeloid Leukemia (AML) following first remission or CR1.Click images below to enlargeRegulators PuntComplete Story » seekingalpha.com |